Page last updated: 2024-08-26

bismuth and Metastase

bismuth has been researched along with Metastase in 22 studies

Research

Studies (22)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (4.55)	18.7374
1990's	3 (13.64)	18.2507
2000's	13 (59.09)	29.6817
2010's	5 (22.73)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bednarz, B; Lee, D; Li, M; Schultz, MK	1
Ding, K; Li, L; Wang, L; Xiao, H; Zhang, J; Zhang, Z; Zhao, H; Zheng, C	1
Apostolidis, C; Boll, R; Bruchertseifer, F; Giesel, FL; Haberkorn, U; Kratochwil, C; Mier, W; Morgenstern, A; Murphy, K	1
Knoesen, O; Marx, S; Meckel, M; Modiselle, M; Sathekge, M; Vorster, M	1
Abbas Rizvi, SM; Allen, BJ; Apostolidis, C; Beretov, J; Cozzi, PJ; Li, Y; Morgenstern, A; Power, CA; Raja, C; Russell, PJ; Song, E	1
Bruchertseifer, F; Lingappa, M; Morgenstern, A; Sgouros, G; Song, H; Thompson, S	1
Allen, BJ; Li, Y; Ranson, M; Rizvi, SM; Tian, Z	1
Lin, HY; McDevitt, MR; Scheinberg, DA; Sgouros, G; Sofou, S; Thomas, JL	1
Allen, BJ; Graham, P; Kearsley, J; Li, Y; Qu, CF; Raja, C; Rizvi, S; Song, E; Thompson, J; Tsui, W; Zhang, D	1
Allen, BJ; Graham, P; Kearsley, J; Li, Y; Raja, C; Reisfeld, RA; Rizvi, S; Thompson, JF; Tsui, W	1
Allen, BJ; Apostolidis, C; Li, Y; Morgenstern, A; Qu, CF; Raja, C; Rizvi, SM; Smith, R; Song, EY	1
Abbas Rizvi, SM; Allen, BJ; Apostolidis, C; Li, Y; Morgenstern, A; Qu, CF; Raja, C; Song, EY	1
Abbas Rizvi, SM; Allen, BJ; Apostolidis, C; Cozzi, PJ; Li, Y; Madigan, MC; Morgenstern, A; Power, CA; Qu, CF; Russell, PJ; Wang, J	1
Abbas Rizvi, SM; Allen, BJ; Apostolidis, C; Brechbiel, MW; Morgenstern, A; Qu, CF; Raja, C; Song, EY	1
Allen, BJ; Graham, P; Raja, C; Rizvi, S; Song, EY	1
Bruchertseifer, F; Huber, T; Kessler, H; Knör, S; Magdolen, V; Morgenstern, A; Sato, S; Schmitt, M; Seidl, C; Senekowitsch-Schmidtke, R	1
Bigner, DD; Zalutsky, MR	1
Boll, R; Kennel, SJ; Mirzadeh, S; Schuller, HM; Stabin, M	1
Allen, BJ	1
Ballangrud, AM; Bander, NH; Charlton, DE; Hamacher, KA; Ma, D; McDevitt, MR; Panageas, KS; Scheinberg, DA; Sgouros, G; Yang, WH	1
Allen, BJ; Andronicos, NM; Ranson, M; Rizvi, S; Tian, Z	1
Arsac, M; Champeau, M; Pineau, P	1

Reviews

2 review(s) available for bismuth and Metastase

Article	Year
Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. Acta oncologica (Stockholm, Sweden), 1996, Volume: 35, Issue:3 Topics: Alpha Particles; Antibodies, Monoclonal; Astatine; Bismuth; Female; Half-Life; Humans; Immunoconjugates; Linear Energy Transfer; Lymphoma; Meningitis; Neoplasm Metastasis; Ovarian Neoplasms; Radioimmunotherapy; Radioisotopes	1996
Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer. Australasian radiology, 1999, Volume: 43, Issue:4 Topics: Alpha Particles; Animals; Astatine; Bismuth; Humans; Immunoconjugates; Mice; Neoplasm Metastasis; Neoplasms; Radioisotopes; Terbium; Tumor Cells, Cultured	1999

Trials

1 trial(s) available for bismuth and Metastase

Article	Year
Intralesional targeted alpha therapy for metastatic melanoma. Cancer biology & therapy, 2005, Volume: 4, Issue:12 Topics: Aged; Aged, 80 and over; Alpha Particles; Antibodies, Bispecific; Antibodies, Monoclonal; Biomarkers, Tumor; Bismuth; Female; Half-Life; Humans; Immunoconjugates; Injections, Intralesional; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Skin Neoplasms; Tissue Distribution	2005

Other Studies

19 other study(ies) available for bismuth and Metastase

Article	Year
Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy. Radiation research, 2018, Volume: 190, Issue:3 Topics: Actinium; Alpha Particles; Beta Particles; Bismuth; Dose-Response Relationship, Radiation; Humans; Lead Radioisotopes; Lutetium; Neoplasm Metastasis; Neoplasms; Radioisotopes; Yttrium Radioisotopes	2018
C-C Chemokine Ligand 2 (CCL2) Recruits Macrophage-Membrane-Camouflaged Hollow Bismuth Selenide Nanoparticles To Facilitate Photothermal Sensitivity and Inhibit Lung Metastasis of Breast Cancer. ACS applied materials & interfaces, 2018, Sep-19, Volume: 10, Issue:37 Topics: Animals; Antineoplastic Agents; Bismuth; Breast Neoplasms; Chemokine CCL2; Female; Hot Temperature; Macrophages; Mice; Mice, Inbred BALB C; Nanoparticles; Neoplasm Metastasis; Organoselenium Compounds; Photosensitizing Agents; Quercetin; RAW 264.7 Cells; Selenium Compounds	2018
²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience. European journal of nuclear medicine and molecular imaging, 2014, Volume: 41, Issue:11 Topics: Adult; Alpha Particles; Beta Particles; Bismuth; Female; Humans; Male; Molecular Targeted Therapy; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Positron-Emission Tomography; Radioisotopes; Receptors, Somatostatin; Retrospective Studies; Tomography, X-Ray Computed; Treatment Failure	2014
European journal of nuclear medicine and molecular imaging, 2017, Volume: 44, Issue:6 Topics: Alpha Particles; Bismuth; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Male; Molecular Targeted Therapy; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes	2017
Inhibition of micrometastatic prostate cancer cell spread in animal models by 213Bilabeled multiple targeted alpha radioimmunoconjugates. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Feb-01, Volume: 15, Issue:3 Topics: Animals; Antibodies, Monoclonal; Bismuth; Cell Line, Tumor; Disease Models, Animal; Humans; Immunoconjugates; Male; Mice; Mice, Nude; Mice, SCID; Neoplasm Metastasis; Neoplasm Transplantation; Prostatic Neoplasms; Radioisotopes; Urokinase-Type Plasminogen Activator	2009
Immunoliposomal delivery of 213Bi for alpha-emitter targeting of metastatic breast cancer. Cancer research, 2010, Sep-01, Volume: 70, Issue:17 Topics: Alpha Particles; Animals; Bismuth; Female; Immunoconjugates; Isothiocyanates; Liposomes; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Neoplasm Metastasis; Pentetic Acid; Radioimmunotherapy; Radioisotopes; Rats; Receptor, ErbB-2	2010
Preclinical studies of targeted alpha therapy for breast cancer using 213Bi-labelled-plasminogen activator inhibitor type 2. British journal of cancer, 2003, Mar-24, Volume: 88, Issue:6 Topics: Alpha Particles; Animals; Bismuth; Breast Neoplasms; Female; Humans; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Neoplasms, Experimental; Plasminogen Activator Inhibitor 2; Serine Proteinase Inhibitors; Tumor Cells, Cultured	2003
Engineered liposomes for potential alpha-particle therapy of metastatic cancer. Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2004, Volume: 45, Issue:2 Topics: Actinium; Alpha Particles; Animals; Bismuth; Humans; Liposomes; Microscopy, Electron; Neoplasm Metastasis; Radioisotopes	2004
Targeted alpha therapy for cancer. Physics in medicine and biology, 2004, Aug-21, Volume: 49, Issue:16 Topics: Alpha Particles; Animals; Antibodies, Monoclonal; Apoptosis; Bismuth; Cell Line, Tumor; Chelating Agents; Clinical Trials as Topic; Female; Flow Cytometry; Humans; Kinetics; Male; Melanoma; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neoplasms; Prostatic Neoplasms; Radioisotopes; Radiotherapy; Sensitivity and Specificity; Skin Neoplasms; Time Factors	2004
Pre-clinical study of 213Bi labeled PAI2 for the control of micrometastatic pancreatic cancer. Clinical & experimental metastasis, 2005, Volume: 22, Issue:7 Topics: Animals; Bismuth; Cell Line, Tumor; Cell Survival; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Microscopy, Confocal; Neoplasm Metastasis; Pancreatic Neoplasms; Plasminogen Activator Inhibitor 2; Radioisotopes; Radiopharmaceuticals; Transplantation, Heterologous; Urokinase-Type Plasminogen Activator	2005
Preclinical studies of bismuth-213 labeled plasminogen activator inhibitor type 2 (PAI2) in a prostate cancer nude mouse xenograft model. Cancer biology & therapy, 2006, Volume: 5, Issue:4 Topics: Animals; Bismuth; Chelating Agents; Cycloheximide; Humans; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Pentetic Acid; Plasminogen Activator Inhibitor 2; Prostatic Neoplasms; Rabbits; Radioisotopes; Serine Proteinase Inhibitors	2006
Control of prostate cancer spheroid growth using 213Bi-labeled multiple targeted alpha radioimmunoconjugates. The Prostate, 2006, Dec-01, Volume: 66, Issue:16 Topics: Alpha Particles; Antibodies, Monoclonal; Antigens, Neoplasm; Bismuth; Cell Line, Tumor; Flow Cytometry; Humans; Immunoconjugates; Immunohistochemistry; Male; Neoplasm Metastasis; Prostatic Neoplasms; Spheroids, Cellular	2006
Pharmacokinetics and toxicity of (213)Bi-labeled PAI2 in preclinical targeted alpha therapy for cancer. Cancer biology & therapy, 2007, Volume: 6, Issue:6 Topics: Alpha Particles; Animals; Bismuth; Chelating Agents; Female; Kidney; Medical Oncology; Mice; Mice, Inbred BALB C; Neoplasm Metastasis; Plasminogen Activator Inhibitor 2; Rabbits; Radioimmunotherapy; Radioisotopes; Time Factors	2007
Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer. Physics in medicine and biology, 2007, Jul-07, Volume: 52, Issue:13 Topics: Alpha Particles; Bismuth; Clinical Trials as Topic; Dose-Response Relationship, Radiation; Humans; Kinetics; Melanoma; Neoplasm Metastasis; Radioisotopes; Radiotherapy; Skin Neoplasms; Time Factors; Treatment Outcome	2007
Development and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancer. European journal of nuclear medicine and molecular imaging, 2008, Volume: 35, Issue:1 Topics: Alpha Particles; Animals; Bismuth; Cell Line, Tumor; Dimerization; Drug Discovery; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Heterocyclic Compounds, 1-Ring; Humans; Kidney; Ligands; Mice; Neoplasm Metastasis; Ovarian Neoplasms; Peptides; Polygeline; Radioisotopes; Receptors, Urokinase Plasminogen Activator; Solubility; Substrate Specificity; Tissue Distribution	2008
Radioimmunotherapy of micrometastases in lung with vascular targeted 213Bi. British journal of cancer, 1999, Volume: 80, Issue:1-2 Topics: Animals; Antibodies, Monoclonal; Bismuth; Dose-Response Relationship, Radiation; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, SCID; Microcirculation; Neoplasm Metastasis; Neoplasm Transplantation; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Rats; Tumor Cells, Cultured	1999
Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer research, 2001, Mar-01, Volume: 61, Issue:5 Topics: Alpha Particles; Antibodies, Monoclonal; Antigens, Surface; Bismuth; Carboxypeptidases; Cell Division; Glutamate Carboxypeptidase II; Humans; Immunotoxins; Male; Microscopy, Confocal; Neoplasm Metastasis; Prostatic Neoplasms; Radioimmunotherapy; Radioisotopes; Spheroids, Cellular; Tumor Cells, Cultured	2001
In vitro cytotoxicity of bismuth-213 (213Bi)-labeled-plasminogen activator inhibitor type 2 (alpha-PAI-2) on human breast cancer cells. Breast cancer research and treatment, 2002, Volume: 71, Issue:2 Topics: Bismuth; Breast Neoplasms; Cell Survival; Female; Humans; Kinetics; Neoplasm Metastasis; Pentetic Acid; Plasminogen Activator Inhibitor 2; Radioisotopes; Recombinant Proteins; Tumor Cells, Cultured	2002
[2 duodenal diverticula and gastric cancer]. La semaine des hopitaux : organe fonde par l'Association d'enseignement medical des hopitaux de Paris, 1968, Jun-14, Volume: 44, Issue:29 Topics: Abdomen; Aged; Antiemetics; Ascorbic Acid; Bismuth; Carcinoma, Basal Cell; Diverticulum; Duodenal Diseases; Epididymitis; Gastrectomy; Humans; Liver Neoplasms; Male; Neoplasm Metastasis; Pain; Stomach Neoplasms; Tracheotomy	1968